Avastin Current Events | Avastin News
|
|
|
Sort By:
Page Views | Date |
Bevacizumab found to improve survival for patients with advanced breast cancer
Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an anti-angiogenic therapy. view more (2007-12-27)
Taxol with avastin produces noteworthy results
The positive results of the first nationwide clinical study showing the benefits of an antiangiogenic agent in breast cancer therapy are reported in the Dec. 27 issue of the New England Journal of Medicine. view more (2007-12-28)
Avastin dramatically improves response, survival in deadly recurrrent glioblastomas
The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred. view more (2009-09-03)
Drug that chokes off tumor blood vessels offers new hope to lung cancer patients
Patients suffering from the most common type of lung cancer experienced a 20-percent improvement in overall survival in a national clinical trial of a drug that chokes off the blood vessels nourishing tumors, a multicenter study has found. view more (2006-12-14)
Northwestern researchers launch Avastin trial for pancreatic tumors
Avastin is designed to inhibit Vascular Endothelial Growth Factor (VEGF), a protein that plays an important role in tumor angiogenesis or blood vessel formation, and maintenance of existing tumor vessels. view more (2006-02-22)
Novel 4-drug combination proves safe for lung cancer treatment
The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center. view more (2008-11-13)
Avastin effective at delaying brain tumor progression in recurrent disease
The use of Avastin alone to treat a subgroup of recurrent Grade 3 brain tumors showed it was safe and effective at delaying tumor progression, according to a retrospective study of 22 patients conducted by a researcher at the Seattle Cancer Care Alliance. view more (2009-04-07)
A crystal ball for brain cancer?
UCLA researchers have uncovered a new way to scan brain tumors and predict which ones will be shrunk by the drug Avastin -- before the patient ever starts treatment. view more (2009-07-30)
Cancer drug is no different in effectiveness as gold standard treatment for macular degeneration
Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). view more (2009-10-12)
Cancer drug can extend survival in patients with deadly brain tumors
Avastin, a relatively new type of drug that shrinks cancerous tumors by cutting off their blood supply, can slow the growth of the most common and deadly form of brain cancer, a pilot study conducted at Duke University Medical Center has found. view more (2007-02-20)
Study finds blocking angiogenesis signaling from inside cell may lead to serious health problems
Angiogenesis inhibitors that block a tumor's development of an independent blood supply have been touted as effective cancer fighters that result in fewer side effects than traditional chemotherapy. view more (2007-08-24)
Lombardi research: Monoclonal antibodies primed to become potent immune weapons against cancer
New research suggests that monoclonal antibody therapy of cancer can be improved to be much more powerful than it is today, says a researcher at Georgetown University Medical Center's Lombardi Comprehensive Cancer Center in the March 21 issue of the Lancet. view more (2009-03-20)
Low-dose chemotherapy plus antiangiogenesis drug has activity in advanced breast cancer
Chemotherapy given in low, frequent doses - a novel strategy called "metronomic" delivery - achieved partial shrinkage of disease in some advanced breast cancer patients when given concurrently with an angiogenesis inhibitor. view more (2005-12-09)
Brain tumor researchers find their 'niche'
Brain tumors appear to arise from cancer stem cells (CSCs) that live within microscopic protective "niches" formed by blood vessels in the brain; and disrupting these niches is a promising strategy for eliminating the tumors and preventing them from re-growing. view more (2007-01-17)
To evade chemotherapy, some cancer cells mimic stem cells
Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented today in Atlanta, Georgia at the American Association for Cancer Research's second International Conference on... view more... (2007-09-20)
Another way to grow blood vessels
Researchers at Dana-Farber Cancer Institute have found a previously unknown molecular pathway in mice that spurs the growth of new blood vessels when body parts are jeopardized by poor circulation. view more (2008-02-21)
Can further studies lower the cost of preserving vision?
The results of two large, randomized clinical trials published October 5, 2006, in the New England Journal of Medicine demonstrate that the drug ranibizumab is an effective treatment for neovascular macular degeneration, a complication of age-related macular degeneration that leads to the vast majority of legal blindness associated with the... view more... (2006-10-05)
Researchers announce new predictor for lung cancer treatment and survival
Research from the Ireland Cancer Center of University Hospitals of Cleveland has found a promising, novel biomarker that may be used to predict the survival of patients with advanced lung cancer and their response to treatment. view more (2006-06-06)
Patient knowledge of health information influences cancer treatment
A new analysis finds that when colorectal cancer patients seek out health information from the internet and news media, they are more likely to be aware of and receive the latest treatments for their disease. view more (2009-02-23)
Study shows microRNA-based diagnostic identifies squamous lung cancer with 96 percent sensitivity
A new study shows for the first time that a microRNA-based diagnostic test can objectively identify squamous lung cancer with 96% sensitivity, according to Harvey Pass, M.D. of the NYU Cancer Institute at NYU Langone Medical Center, one of the authors of the study published on-line ahead of print in the Journal of Clinical Oncology. view more (2009-03-10)
|
|
|
|
Sort By:
Page Views | Date |
|
